Influenza Vaccines

"Influenza Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more INFLUENZAVIRUS A and INFLUENZAVIRUS B strains.

Descriptor ID	D007252
MeSH Number(s)	D20.215.894.899.302
Concept/Terms	Influenza Vaccines Influenza Vaccines Influenza Vaccine Vaccine, Influenza Flu Vaccines Influenzavirus Vaccines Influenza Virus Vaccines Influenza Virus Vaccine Vaccine, Influenza Virus Virus Vaccine, Influenza High-Dose Trivalent Influenza Vaccine High-Dose Trivalent Influenza Vaccine High Dose Trivalent Influenza Vaccine Monovalent Influenza Vaccines Monovalent Influenza Vaccines Influenza Vaccines, Monovalent Vaccines, Monovalent Influenza Trivalent Influenza Vaccine Trivalent Influenza Vaccine Influenza Vaccine, Trivalent Vaccine, Trivalent Influenza Intranasal Live-Attenuated Influenza Vaccine Intranasal Live-Attenuated Influenza Vaccine Intranasal Live Attenuated Influenza Vaccine Universal Flu Vaccines Universal Flu Vaccines Universal Influenza Vaccines Trivalent Live Attenuated Influenza Vaccine Trivalent Live Attenuated Influenza Vaccine LAIV Vaccine Vaccine, LAIV Quadrivalent Influenza Vaccine Quadrivalent Influenza Vaccine Influenza Vaccine, Quadrivalent Vaccine, Quadrivalent Influenza

Below are MeSH descriptors whose meaning is more general than "Influenza Vaccines".

Chemicals and Drugs [D]
Complex Mixtures [D20]
Biological Products [D20.215]
Vaccines [D20.215.894]
Viral Vaccines [D20.215.894.899]
Influenza Vaccines [D20.215.894.899.302]

Below are MeSH descriptors whose meaning is more specific than "Influenza Vaccines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Influenza Vaccines" by people in this website by year, and whether "Influenza Vaccines" was a major or minor topic of these publications.

Bar chart showing 63 publications over 23 distinct years, with a maximum of 8 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	2	0	2
2001	0	1	1
2003	2	1	3
2004	2	0	2
2006	1	1	2
2007	1	1	2
2008	6	0	6
2009	1	0	1
2011	2	1	3
2012	1	0	1
2013	2	0	2
2014	1	0	1
2015	1	0	1
2016	2	3	5
2017	1	1	2
2018	2	0	2
2019	2	1	3
2020	2	0	2
2021	4	3	7
2022	8	0	8
2023	3	0	3
2024	3	0	3
2025	1	0	1

Below are the most recent publications written about "Influenza Vaccines" by people in Profiles.

Khan A, Zhu Y, Babcock HM, Busse LW, Duggal A, Exline MC, Gaglani M, Gibbs KW, Gong MN, Ginde AA, Hager DN, Hope AA, Hyde J, Johnson NJ, Kwon JH, Mohr NM, O'Rourke M, Peltan ID, Mallow C, Qadir N, Reddy R, Safdar B, Shapiro NI, Sohn I, Steingrub JS, Wilson JG, Baughman A, Womack KN, Rhoads JP, Self WH, Stubblefield WB. COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022. Vaccine. 2025 Feb 27; 48:126806.

View in: PubMed
Lewis NM, Harker EJ, Leis A, Zhu Y, Talbot HK, Grijalva CG, Halasa N, Chappell JD, Johnson CA, Rice TW, Casey JD, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, DeCuir J, Surie D, Dawood FS, Ellington S, Self WH, Martin ET. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2025 Jan 01; 43(Pt 2):126492.

View in: PubMed
Lewis NM, Zhu Y, Peltan ID, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Duggal A, Bender WS, Taghizadeh L, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Qadir N, Chang SY, Ginde AA, Mohr NM, Mallow C, Lauring AS, Johnson NJ, Gibbs KW, Kwon JH, Columbus C, Gottlieb RL, Raver C, Vaughn IA, Ramesh M, Johnson C, Lamerato L, Safdar B, Casey JD, Rice TW, Halasa N, Chappell JD, Grijalva CG, Talbot HK, Baughman A, Womack KN, Swan SA, Harker E, Price A, DeCuir J, Surie D, Ellington S, Self WH. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 04 10; 78(4):1056-1064.

View in: PubMed
Surie D, Yuengling KA, DeCuir J, Zhu Y, Lauring AS, Gaglani M, Ghamande S, Peltan ID, Brown SM, Ginde AA, Martinez A, Mohr NM, Gibbs KW, Hager DN, Ali H, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Leis AM, Khan A, Hough CL, Bender WS, Duggal A, Bendall EE, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Exline MC, Shapiro NI, Columbus C, Vaughn IA, Ramesh M, Mosier JM, Safdar B, Casey JD, Talbot HK, Rice TW, Halasa N, Chappell JD, Grijalva CG, Baughman A, Womack KN, Swan SA, Johnson CA, Lwin CT, Lewis NM, Ellington S, McMorrow ML, Martin ET, Self WH. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024 04 01; 7(4):e244954.

View in: PubMed
Fisher KA, Nguyen N, Fouayzi H, Crawford S, Singh S, Dong M, Wittenberg R, Mazor KM. From COVID-19 Vaccine Hesitancy to Vaccine Acceptance: Results of a Longitudinal Survey. Public Health Rep. 2023 Jul-Aug; 138(4):681-690.

View in: PubMed
Tenforde MW, Patel MM, Lewis NM, Adams K, Gaglani M, Steingrub JS, Shapiro NI, Duggal A, Prekker ME, Peltan ID, Hager DN, Gong MN, Exline MC, Ginde AA, Mohr NM, Mallow C, Martin ET, Talbot HK, Gibbs KW, Kwon JH, Chappell JD, Halasa N, Lauring AS, Lindsell CJ, Swan SA, Hart KW, Womack KN, Baughman A, Grijalva CG, Self WH. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis. 2023 03 21; 76(6):1030-1037.

View in: PubMed
Geissler KH, Shieh MS, Evans V, Lindenauer PK, Ash AS, Krishnan JA, Goff SL. Influenza Vaccinations Among Privately and Publicly Insured Children With Asthma. Acad Pediatr. 2023 Sep-Oct; 23(7):1368-1375.

View in: PubMed
Turbyfill C, Adams K, Tenforde MW, Murray NL, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW, Clark Files D, Hager DN, Shehu A, Prekker ME, Frosch AE, Exline MC, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Lauring AS, Khan A, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, June Gordon A, Qadir N, Chang SY, Mallow C, Rivas C, Kwon JH, Halasa N, Chappell JD, Grijalva CG, Rice TW, Stubblefield WB, Baughman A, Rhoads JP, Lindsell CJ, Hart KW, McMorrow M, Surie D, Self WH, Patel MM. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 11 15; 40(48):6979-6986.

View in: PubMed
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews JI, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. JCI Insight. 2022 10 10; 7(19).

View in: PubMed
Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Ghamande SA, McNeal TA, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Busse LW, Lohuis CCT, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Lauring AS, Halasa N, Chappell JD, Grijalva CG, Rice TW, Rhoads JP, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Adams K, Patel MM, Tenforde MW. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S159-S166.

View in: PubMed

People

Explore

Similar Concepts

Top Journals